{"entity":{"id":"nct05522660","kind":"trial","name":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer","aka":["USZ-STRIKE"],"tldr":"A phase 3 trial in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","summary":"Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT05522660 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 180 participants, started 2022-11-30 and due to reach its primary completion in 2026-09. Interventions recorded: Stereotactic radiosurgery; Immune checkpoint inhibitor. Conditions listed: Non-Small Cell Lung Cancer; Melanoma. Primary outcome: CNS-specific PFS, locally assessed as per iRANO criteria. Lung eligibility wording from the registry: \"* Primary disease of histologically confirmed (from primary tumour or from a metastatic lesion, including in the brain) melanoma or NSCLC\". Sites: Italy, Netherlands, Spain, Switzerland, United Kingdom. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05522660","url":"https://clinicaltrials.gov/study/NCT05522660"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":["etop-ibcsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Royal Marsden (Sutton) (London); Christie NHS Manchester (Manchester)."],"nct":"NCT05522660","phase":"3","setting":"A Multicentre Randomised Open-label Phase III Study of Stereotactic Radiosurgery, in Addition to Standard Systemic Therapy for Patients With Metastatic Melanoma or Newly Diagnosed Metastatic NSCLC and Asymptomatic or Oligo-symptomatic Brain Metastases","sponsor":"ETOP IBCSG Partners Foundation","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05522660/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"company":[{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}